Ampyra and Weakness - a phase IV clinical study of FDA data
Summary:
Weakness is found among people who take Ampyra, especially for people who are female, 60+ old, have been taking the drug for < 1 month.
The phase IV clinical study analyzes which people take Ampyra and have Weakness. It is created by eHealthMe based on reports of 75,087 people who have side effects when taking Ampyra from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.
Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.
75,087 people reported to have side effects when taking Ampyra.
Among them, 6,572 people (8.75%) have Weakness.
What is Ampyra?
Ampyra has active ingredients of dalfampridine. It is often used in multiple sclerosis. eHealthMe is studying from 75,229 Ampyra users for its effectiveness, alternative drugs and more.
What is Weakness?
Weakness is found to be associated with 5,239 drugs and 6,223 conditions by eHealthMe.
Number of Ampyra and Weakness reports submitted per year:
Time on Ampyra when people have Weakness *:
Gender of people who have Weakness when taking Ampyra*:
Age of people who have Weakness when taking Ampyra *:
Common drugs people take besides Ampyra *:
Common side effects people have besides Weakness *:
Common conditions people have *:
* Approximation only. Some reports may have incomplete information.
Do you take Ampyra and have Weakness?
Check whether Weakness is associated with a drug or a conditionHow to use the study?
You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
Related studies
How severe was Weakness and when was it recovered:
Expand to all the drugs that have ingredients of dalfampridine:
- Weakness and drugs with ingredients of dalfampridine (6,115 reports)
Alternative drugs to, pros and cons of Ampyra:
- Ampyra (75,229 reports)
Common Ampyra side effects:
- Drug ineffective: 8,776 reports
- Weakness: 6,572 reports
- Fatigue (feeling of tiredness): 6,118 reports
- Urinary tract infection: 4,633 reports
Browse all side effects of Ampyra:
a b c d e f g h i j k l m n o p q r s t u v w x y zWeakness treatments and more:
- Weakness (513,318 reports)
COVID vaccines that are related to Weakness:
- Weakness in Moderna COVID Vaccine
- Weakness in Pfizer BioNTech Covid Vaccine
- Weakness in Johnson and Johnson Covid Vaccine
Common drugs associated with Weakness:
- Prednisone: 26,970 reports
- Aspirin: 26,881 reports
- Humira: 16,920 reports
- Methotrexate: 16,130 reports
- Metformin: 15,821 reports
- Omeprazole: 15,424 reports
- Tysabri: 14,800 reports
- Lisinopril: 14,469 reports
- Lipitor: 14,239 reports
- Synthroid: 13,523 reports
All the drugs that are associated with Weakness:
- Weakness (5,239 drugs)
Common conditions associated with Weakness:
- Multiple sclerosis: 44,040 reports
- High blood pressure: 24,528 reports
- Rheumatoid arthritis: 22,785 reports
- High blood cholesterol: 17,735 reports
- Pain: 15,184 reports
- Osteoporosis: 13,578 reports
All the conditions that are associated with Weakness:
- Weakness (6,223 conditions)
How the study uses the data?
The study uses data from the FDA. It is based on dalfampridine (the active ingredients of Ampyra) and Ampyra (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
Who is eHealthMe?
With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Rabeprazole Sodium and Muscle Cramps Aggravated - 10 seconds ago
- Vitamin Supplementation and Osgood-Schlatter Disease - 18 seconds ago
- Lacosamide and Vitreous Floaters - 55 seconds ago
- Simvastatin and Mellaril drug interaction - a minute ago
- Levaquin and Withdrawal Syndrome - a minute ago
- Nasonex and Blood Bilirubin Increased - a minute ago
- Cambia and Inderal drug interaction - 2 minutes ago
- Stelara and Oedema - 2 minutes ago
- Abstral and Naloxone drug interaction - 3 minutes ago
- Diovan Hct and Colon Cancer Stage Iii - 4 minutes ago